Tirzepatide and pregnancy: what the evidence actually says

Last updated 2026-07-30

Is tirzepatide safe to take during pregnancy?

No one knows for sure, because it hasn't been tested in pregnant women, and the honest answer is that both manufacturer labels tell you not to use it if you're pregnant or planning to become pregnant soon. The Zepbound (tirzepatide for weight loss) prescribing information states plainly that the drug "is not recommended for use during pregnancy" ^[1]. The Mounjaro (tirzepatide for type 2 diabetes) label carries similar language ^[2]. Neither approval included pregnant participants in the core trials, so everything you'll read below is inference from animal studies, pharmacology, and general caution around GLP-1/GIP drugs as a class, not human outcome data. That's a real gap. Tirzepatide is a fairly new molecule, FDA-approved for type 2 diabetes in May 2022 and for chronic weight management in November 2023 ^[3][4]. Registries that track pregnancy exposures to newer drugs take years to accumulate enough cases to say anything statistically meaningful. Right now, that registry data for tirzepatide essentially doesn't exist in published form.

What did animal studies show about tirzepatide and fetal development?

Animal reproduction studies in rats and rabbits found reduced fetal weight, skeletal variations, and structural abnormalities at maternal drug exposures relevant to or below the human exposure at the highest approved dose. The Zepbound label describes "embryo-fetal toxicity" in these studies, including decreased fetal body weight and increased incidence of major fetal abnormalities in rabbits at clinically relevant exposure levels ^[1]. Animal studies don't translate directly to humans. Rodent and rabbit models often overstate or understate real human risk, and regulators know that. But they're the only red flag we have right now, and the FDA used them to justify the pregnancy warning rather than leaving it silent. The label's own reasoning ties the finding to reduced maternal food intake and the resulting weight loss in the pregnant animals, which raises a separate point worth sitting with: a drug this good at cutting appetite and slowing gastric emptying could plausibly affect fetal nutrition through the mother's calorie intake alone, independent of any direct toxic effect on the fetus ^[1].

How long before pregnancy should you stop tirzepatide?

Both labels recommend stopping tirzepatide at least 1 month before a planned pregnancy. This isn't an arbitrary number pulled from nowhere. Tirzepatide has a long elimination half-life of about 5 days ^[1][2], meaning it takes roughly 5 half-lives, around 25 to 30 days, for the drug to clear from your system to a level considered clinically insignificant. A 1-month washout lines up with that pharmacokinetic reality. If you're on tirzepatide for weight loss and thinking about conceiving in the next few months, talk to your prescriber now rather than waiting. Stopping any GLP-1/GIP drug typically means some regain of appetite and, over time, weight, so you and your provider may want to plan the taper and the conception timeline together rather than stopping cold on short notice.

What happens if you get pregnant while taking tirzepatide?

Stop the medication and call your prescriber as soon as you know or suspect you're pregnant. Don't panic, but don't keep dosing either. There's no antidote or reversal agent needed. Tirzepatide isn't dosed daily; it's a once-weekly injection, so if you conceived partway through a dosing cycle, you simply don't take the next scheduled dose. Your OB team will want to know the timing of your last dose and your dosing history so they can factor that into monitoring, though there's no established protocol demanding extra ultrasounds or testing specifically because of tirzepatide exposure. Most obstetric guidance in this situation is judgment-based rather than protocol-based, precisely because the human outcome data doesn't exist yet to justify a specific surveillance schedule. If you were taking tirzepatide for type 2 diabetes, this is also the moment to loop in your diabetes care team, since glycemic control in early pregnancy matters a lot for fetal development and you'll likely be transitioned to a pregnancy-appropriate regimen (often insulin, which has a long safety track record in pregnancy).

Does tirzepatide affect birth control effectiveness?

Yes, potentially, and this is one of the more practically important warnings on the label. Tirzepatide slows gastric emptying, which can reduce the absorption of oral medications taken around the same time, including oral contraceptive pills ^[1][2]. The Zepbound label specifically advises that women using oral hormonal contraceptives should switch to a non-oral contraceptive method, or add a barrier method, for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase ^[1]. This window matters because dose increases happen repeatedly during titration, tirzepatide typically escalates from 2.5 mg up through 5, 7.5, 10, 12.5, and up to 15 mg over months, and the absorption effect on other oral drugs is thought to be most pronounced right after a dose change, before gastric emptying re-stabilizes. Practically: if you're relying on the pill and don't want to get pregnant while on tirzepatide, ask your provider about a backup method (condoms, or switching to an IUD or implant) at least through the first month of treatment and the first month after every dose bump.

Can tirzepatide affect fertility or ovulation?

Indirectly, yes, and this trips up more people than the pregnancy warning itself. Significant weight loss can restore ovulation in women who weren't ovulating regularly because of obesity-related conditions like PCOS. Tirzepatide isn't approved or marketed as a fertility treatment, but by driving meaningful weight loss (up to 20.9% of body weight at the highest dose over 72 weeks in the SURMOUNT-1 trial) ^[5], it can unmask fertility that obesity was suppressing. This means someone who wasn't at real risk of pregnancy before starting tirzepatide might become fertile again a few months into treatment, sometimes without expecting it. If pregnancy isn't the goal right now, this is exactly why the contraception guidance above isn't a formality. Providers who prescribe tirzepatide to women of reproductive age should be raising this directly, not leaving it to the patient to connect the dots.

Is tirzepatide safe while breastfeeding?

The data here is thinner than the pregnancy data, which is saying something. The Zepbound label notes there's no information on the presence of tirzepatide in human milk, its effects on the breastfed infant, or its effects on milk production ^[1]. The label advises weighing the developmental and health benefits of breastfeeding against the mother's clinical need for tirzepatide and any potential adverse effects on the breastfed infant. Tirzepatide is a large peptide molecule, and large peptides are generally poorly absorbed from breast milk into an infant's bloodstream because they get broken down in the infant's gut like any other protein. That's a plausibility argument, not evidence. Nobody has published a controlled study measuring tirzepatide levels in human milk or infant outcomes, so this is an area where you and your provider are making a judgment call under real uncertainty, not following an established safety record.

What is the MEN2 and thyroid cancer warning, and does it matter for pregnancy planning?

Tirzepatide carries a boxed warning, the FDA's strongest warning label, for thyroid C-cell tumors observed in rodent studies, and it's contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) ^[1][2]. This isn't specific to pregnancy, but it's worth knowing as part of the full safety picture before you decide whether tirzepatide is right for you at all, pregnancy plans aside. The boxed warning states that tirzepatide "is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2" ^[1]. If that family history applies to you, this drug is off the table regardless of pregnancy timing, and you'd want to discuss alternative weight-loss or diabetes strategies with your provider.

What other side effects and contraindications should pregnant or conceiving women know about?

Beyond the pregnancy-specific warnings, tirzepatide's most common side effects are gastrointestinal: nausea, diarrhea, decreased appetite, vomiting, constipation, and abdominal pain, reported by a substantial share of participants in the SURMOUNT-1 trial (nausea alone in about 24 to 33% of participants depending on dose, versus about 10% on placebo) ^[5]. These usually ease over the first weeks of a dose or a dose increase. More serious but less common risks include acute pancreatitis, gallbladder problems (cholelithiasis and cholecystitis), acute kidney injury (often linked to dehydration from vomiting or diarrhea), and severe hypoglycemia when tirzepatide is combined with insulin or sulfonylureas ^[1][2]. There's also a warning about diabetic retinopathy complications in patients with type 2 diabetes, drawn from the SURPASS program. None of these are pregnancy-specific, but severe vomiting or dehydration is obviously a bigger concern in pregnancy than outside it, and gallbladder disease incidence tends to rise in pregnancy anyway for unrelated hormonal reasons, so these risks could compound. The drug is also not recommended if you have a personal history of pancreatitis, and providers typically use caution in anyone with a history of severe GI disease, given how central the gastric-emptying effect is to how tirzepatide works.

How does tirzepatide's pregnancy warning compare to other GLP-1 drugs like semaglutide?

The caution is essentially the same across the class. Semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda, Victoza) carry comparable "not recommended during pregnancy" language, similar animal-study-based reasoning, and similar advice to discontinue before a planned pregnancy, generally citing a washout of about 2 months for semaglutide given its longer half-life (about 1 week) versus tirzepatide's roughly 5-day half-life. None of the approved GLP-1/GIP drugs for weight loss or type 2 diabetes have been established as safe in human pregnancy, and none are approved for use during pregnancy. | Drug (brand) | Half-life | Labeled pregnancy stance | Suggested pre-conception washout |

Does it matter whether you use brand-name Zepbound/Mounjaro versus compounded tirzepatide?

For the pregnancy question specifically, the biological risk is tied to the tirzepatide molecule itself, not the packaging, so the underlying caution applies whether you're on FDA-approved Zepbound or Mounjaro, or a compounded version obtained through a telehealth platform or compounding pharmacy. But there's an important practical difference. FDA-approved Zepbound and Mounjaro went through the agency's full review process, which is why they carry an FDA-vetted label with specific pregnancy, lactation, and contraception language backed by the manufacturer's animal and human trial data ^[1][2]. Compounded tirzepatide is not FDA-approved, is not required to carry that same standardized labeling, and its exact formulation, dose accuracy, and even active ingredient purity can vary by pharmacy since it isn't manufactured or verified the same way. The FDA has published warnings about adverse event reports tied to compounded semaglutide products, including dosing errors from compounding pharmacies using different salt forms of the drug ^[6]. If you're currently on any version of tirzepatide and pregnancy is on your mind, that's a conversation for a licensed prescriber who has your actual medical history, not a generic label. A provider-reviewed source, like the clinicians Tirz Rx works with through its fulfilling pharmacy partners, can walk through your specific timeline, your contraception method, and your dosing history rather than leaving you to interpret a package insert alone.

What should you do if you're planning pregnancy while on tirzepatide?

Start the conversation with your prescriber as soon as pregnancy enters your plans, ideally a few months out rather than a few weeks out. Because of the roughly 1-month washout recommendation and the fact that stopping the drug often means some return of appetite and weight regain, a rushed stop right before trying to conceive isn't ideal for anyone. A reasonable sequence looks like this: confirm your contraception is reliable during the taper (given the oral-contraceptive absorption warning above), plan the last dose with your prescriber to hit that roughly 1-month clearance window before you start trying, and set up your OB or midwifery care early so any pre-existing conditions (diabetes, gallbladder history, thyroid history) are already on file before you conceive. If you're using tirzepatide for weight management and you're also tracking your progress against tirzepatide before and after benchmarks or a tirzepatide results timeline, build the pregnancy plan into that timeline rather than treating it as an unrelated event that interrupts it.

Frequently asked questions

Can you take tirzepatide while trying to get pregnant?

No. Both the Zepbound and Mounjaro labels recommend discontinuing tirzepatide at least 1 month before a planned pregnancy, based on animal studies showing fetal harm and the drug's roughly 5-day half-life, which means it takes about a month to clear the body to a clinically insignificant level.

What happens if I accidentally get pregnant on tirzepatide?

Stop taking it and contact your prescriber right away. There's no reversal treatment needed since it's a once-weekly injection, so you simply skip future doses. Your OB team will factor your dosing history into monitoring, though there's no specific testing protocol required solely because of tirzepatide exposure.

Does tirzepatide cause birth defects?

Human data doesn't exist yet to answer this directly. Animal studies in rats and rabbits found reduced fetal weight and increased structural abnormalities at clinically relevant exposure levels, which is why the FDA label says tirzepatide is not recommended during pregnancy, but no controlled human studies have measured birth defect rates.

How long does tirzepatide stay in your system before pregnancy is safe?

Tirzepatide has an elimination half-life of about 5 days, and it takes roughly 5 half-lives (about 1 month) to clear to a clinically insignificant level. Both the Zepbound and Mounjaro labels use that timeframe as the basis for their at-least-1-month pre-conception washout recommendation.

Can tirzepatide make you more fertile?

Indirectly, yes. Significant weight loss, up to about 20.9% of body weight at the highest dose in the SURMOUNT-1 trial, can restore ovulation in women whose cycles were disrupted by obesity or PCOS. Tirzepatide isn't a fertility drug, but unmasking previously suppressed ovulation is a real and documented mechanism.

Does tirzepatide affect birth control pills?

Yes. Tirzepatide slows gastric emptying, which can reduce oral drug absorption, including oral contraceptives. The label advises switching to a non-oral contraceptive or adding a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase during titration.

Is it safe to breastfeed while taking tirzepatide?

There's no published data on whether tirzepatide passes into human milk or affects a breastfed infant. The label says to weigh the benefits of breastfeeding against the mother's clinical need for the drug. As a large peptide, it's plausibly poorly absorbed by an infant's gut, but that's inference, not confirmed safety data.

Should I stop tirzepatide immediately if I find out I'm pregnant?

Yes, stop taking it and call your prescriber promptly rather than continuing doses while you wait for an appointment. Since tirzepatide is dosed weekly, stopping simply means skipping the next scheduled injection; there's no need for a tapering schedule or reversal agent.

Is compounded tirzepatide riskier during pregnancy than brand-name Zepbound or Mounjaro?

The core pregnancy risk comes from the tirzepatide molecule itself, so it applies to both forms. But compounded versions aren't FDA-approved, don't carry the same standardized labeling, and can vary in formulation and dose accuracy by pharmacy, which adds uncertainty on top of the already-limited pregnancy safety data.

Can men on tirzepatide affect a partner's pregnancy?

There's no established evidence that tirzepatide use by a male partner affects fetal development, since the drug doesn't appear in the FDA labeling with paternal exposure warnings. The pregnancy warnings on both labels are specific to people who could become pregnant or who are pregnant themselves.

Does having gestational or type 2 diabetes change the tirzepatide pregnancy advice?

No, the same discontinue-before-conception guidance applies. Women with type 2 diabetes who become pregnant are typically transitioned to pregnancy-established treatments like insulin, since glycemic control matters heavily for fetal development and insulin has a far longer track record of safety data in pregnancy than tirzepatide does.

How soon after stopping tirzepatide will my appetite come back before I try to conceive?

This varies by person, but many people notice appetite returning within a few weeks of the last dose as tirzepatide clears (half-life about 5 days). Discuss a taper and conception timeline with your prescriber together, since stopping abruptly right before trying to conceive can mean weight regain overlapping with early pregnancy planning.

Sources

1. FDA, Zepbound (tirzepatide) Prescribing Information: Pregnancy warning, embryo-fetal toxicity in animal studies, contraception timing, half-life, lactation statement, boxed warning language
2. FDA, Mounjaro (tirzepatide) Prescribing Information: Pregnancy warning, contraindication for MTC/MEN2, contraception guidance for Mounjaro
3. FDA, FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes: Mounjaro (tirzepatide) approved for type 2 diabetes in May 2022
4. FDA, FDA Approves New Medication for Chronic Weight Management: Zepbound (tirzepatide) approved for chronic weight management in November 2023
5. NEJM, Jastreboff et al., Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1): Up to 20.9% mean body weight reduction at 72 weeks; nausea incidence by dose group
6. FDA, Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss: FDA warnings on compounded GLP-1 products, dosing errors, and salt-form variation risks